secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001628280-24-048830
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley
-------------------------------------------------------------------------

- Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.
- Roth Capital Partners added as Sales Agent; B. Riley Securities removed.
- Raymond James & Associates and Roth Capital Partners remain as the two Sales Agents.
- No changes to the $0.001 par value common stock or ATM program terms beyond agent roster.
- Agreement governs at-the-market equity offering program for ChromaDex common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/0001628280-24-048830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-048830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer